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Abstract
Background:  HNSCC progression to adjacent tissue and nodes may be mediated by altered
glycoproteins and glycolipids such as MUC1 mucin. This report constitutes a detailed statistical study
about MUC1 expression and anti-MUC1 immune responses in relation to different clinical and pathological
parameters which may be useful to develop new anti HNSCC therapeutic strategies.
Patients and methods: Fifty three pre treatment HNSCC patients were included: 26 (49.1%) bearing
oral cavity tumors, 17 (32.1%) localized in the larynx and 10 (18.8%) in the pharynx. Three patients (5.7%)
were at stage I, 5 (9.4%) stage II, 15 (28.3%) stage III and 30 (56.6%) at stage IV. MUC1 tumor expression
was studied by immunohistochemistry employing two anti-MUC1 antibodies: CT33, anti cytoplasmic tail
MUC1 polyclonal antibody (Ab) and C595 anti-peptidic core MUC1 monoclonal antibody. Serum levels of
MUC1 and free anti-MUC1 antibodies were detected by ELISA and circulating immune complexes (CIC)
by precipitation in polyethylene glycol (PEG) 3.5%; MUC1 isolation from circulating immune complexes
was performed by protein A-sepharose CL-4B affinity chromatography followed by SDS-PAGE and
Western blot. Statistical analysis consisted in Multivariate Principal Component Analysis (PCA); ANOVA
test (Tukey's test) was employed to find differences among groups; nonparametrical correlations
(Kendall's Tau) were applied when necessary. Statistical significance was set to p < 0.05 in all cases.
Results: MUC1 cytoplasmic tail was detected in 40/50 (80%) and MUC1 protein core in 9/50 (18%)
samples while serum MUC1 levels were elevated in 8/53 (15%) patients. A significant statistical correlation
was found between MUC1 serum levels and anti-MUC1 IgG free antibodies, while a negative correlation
between MUC1 serum levels and anti-MUC1 IgM free antibodies was found. Circulating immune
complexes were elevated in 16/53 (30%) samples and were also statistically associated with advanced
tumor stage. MUC1 was identified as an antigenic component of IgG circulating immune complexes.
Moreover, poorly differentiated tumors were inversely correlated with tumor and serum MUC1 detection
and positively correlated with node involvement and tumor mass.
Conclusion:  Possibly, tumor cells produce MUC1 mucin which is liberated to the circulation and
captured by IgG antibodies forming MUC1-IgG-CIC. Another interesting conclusion is that poorly
differentiated tumors are inversely correlated with tumor and serum MUC1 detection.
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Background
In western countries, head and neck squamous cell carci-
noma (HNSCC) occupies the 5th place in frequency and
also is the 5th cause of mortality due to cancer. HNSCC
localization consists about 40% in the oral cavity, 15% in
the pharynx, 25% in the larynx and the rest sites such as
salivary glands and thyroid [1,2]. Data obtained from
argentinian records show some differences compared
with data found in other countries since the most frequent
localization has been larynx (1665/3127, 53%) followed
by oral cavity (1035/3127, 33%) and finally, pharynx
showing 427/3127, 14%. In 2002, the total number of
HNSCC cases informed in Argentina was 3127 (16.9/
100000) inhabitants [3].
Worldwide, delayed diagnosis is common and frequently
very scarce improvement in five-year survival over the last
four decades has been observed [4].
HNSCC mainly progress to adjacent tissue and nodes
while distant metastasis is a late event. The ability of
tumor cells to invade is an acquired and progressive phe-
nomenon mediated, in many cases, by the alteration of
membrane glycoproteins such as mucins. Dabelsteen and
Gao [5] proposed that the presence of different glycosyla-
tion patterns modulate the behavior of these membrane
glycoproteins involved in cell signaling. In adenocarci-
noma, particular interest has been focused on MUC1
mucin; in previous publications we have extensively
detected MUC1 and associated epitopes in HNSCC and
also we have isolated this mucin from larynx primary
squamous cell carcinoma [6-8]. MUC1 is a large het-
erodimeric glycoprotein formed by a highly glycosilated
extracellular portion associated to a small cytoplasmic tail
[9].
Studies developed on different carcinoma localizations
such as breast cancer [10,11] have proved that MUC1
mucin can elicit a humoral immune response; further-
more, we have detected free and complexed anti-MUC1
antibodies in serum samples belonging to breast cancer
patients [12].
This report constitutes a detailed statistical study about
MUC1 expression and anti-MUC1 immune response
related to different clinical and pathological parameters
which may be useful to increase our knowledge to
develop new anti HNSCC therapeutic strategies based on
immunological tools.
Here, we present data that confirm a high tumor MUC1
expression in HNSCC which correlates positively with cir-
culating MUC1. Also, a positive correlation was found
between serum MUC1 versus anti-MUC1 IgG free anti-
bodies.
In addition, circulating immune complexes levels were
statistically associated with tumor size, inversely associ-
ated with MUC1 tumor expression and were not posi-
tively associated with serum MUC1 and free anti-MUC1
IgG. Finally, tumor size, node involvement and poor dif-
ferentiation were positively associated.
Methods
Patients
Fifty three pre treatment HNSCC patients from the "Hos-
pital General Interzonal de Agudos Gral. San Martín", La
Plata, Argentina were included in this study (Table 1); all
tumors were primary; patients with previous history of
HNSCC or who had received preoperative therapy were
not included. Patients were clinically categorized accord-
ing to the American Joint Cancer Committee (AJCC, Can-
cer Staging Manual, 2002). Sex and age distribution of
patients was: 39 males (73.6%) and 14 (26.4%) females
with a mean age of 60.67 (11.55 SD) years and a range
from 29 to 98 years. Twenty six patients (49.1%) had their
primary tumor located in the oral cavity, 17 (32.0%) in
the larynx and 10 (18.9%) in the pharynx. Three patients
(5.7%) were at stage I, 5 (9.4%) at stage II, 15 (28.3%) at
stage III and 30 (56.6%) at stage IV; stages IVA, IVB and
IVC cases where also included. Eighteen were classified as
well differentiated (34.6%), 19 as moderately differenti-
ated (36.5%) and 15 as poorly differentiated (28.9%).
Patient's data were obtained from clinical records.
Informed consent was obtained in accordance with the
Hospital Ethical Commission and the World Medical
Association Declaration of Helsinki: Ethical Principles for
Medical Research Involving Human Subjects (Helsinki,
Finland, 1964 and their modifications).
From each patient, blood and tumor samples were stud-
ied; blood samples were obtained before surgery. Serum
aliquots were frozen at -70°C until use while tumor sam-
ples were immediately fixed in methacarn (60% metha-
nol, 30% chloroform and 10% acetic acid) for two hours
and finally placed in 70% ethanol.
Controls
Eighteen serum samples belonging to normal individuals
sex and age matched were included as a negative control
group in all assays. Ten newly diagnosed pre treatment
patients with systemic lupus erythematosus (SLE) were
included as a positive control group for circulating
immune complex assays.
Antibodies (Abs)
The following antibodies were employed: C595, an IgG3
mouse monoclonal antibody directed to de APDTR
sequence in the variable number tandem repeats of
MUC1 protein core, kindly provided by Dr. A Murray andBMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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Table 1: Patient's clinical data.
Patient 
Number
Age Sex Localization T stage N stage Metastasis Clinical stage Tumor 
differentiation
15 2 M L a r y n x 100I P o o r l y
29 8 M L a r y n x 100I W e l l
37 3 M L a r y n x 100I W e l l
45 7 M O r a l  c a v i t y 200I IP o o r l y
56 5 FL a r y n x 200I IW e l l
66 8 M O r a l  c a v i t y 200I IW e l l
76 4 FO r a l  c a v i t y 200I IW e l l
86 3 M P h a r y n x 200I IW e l l
9 50 M Oral cavity 2 1 0 III Moderately
10 64 M Larynx 3 1 0 III Well
11 48 F Oral cavity 3 1 0 III Poorly
12 47 F Oral cavity 3 1 0 III Well
13 77 M Oral cavity 3 1 0 III Poorly
14 59 M Oral cavity 3 1 0 III Well
15 69 F Oral cavity 3 0 0 III Well
16 56 M Larynx 3 0 0 III Moderately
17 65 M Oral cavity 3 0 0 III Well
18 40 F Oral cavity 3 0 0 III Poorly
19 56 M Pharynx 3 0 0 III Poorly
20 70 M Larynx 3 0 0 III Moderately
21 75 M Pharynx 3 0 0 III Well
22 65 M Oral cavity 3 1 0 III Well
23 60 F Oral cavity 2 1 0 III Moderately
2 4 5 6 M P h a r y n x 400I V A M o d e r a t e l y
2 5 5 4 FP h a r y n x 400I V A P o o r l y
2 6 5 5 M O r a l  c a v i t y 420I V A M o d e r a t e l y
2 7 6 5 M P h a r y n x 420I V A M o d e r a t e l y
2 8 5 8 M L a r y n x 400I V A P o o r l y
2 9 5 3 M L a r y n x 400I V A M o d e r a t e l y
3 0 6 2 M O r a l  c a v i t y 420I V A N D
3 1 2 9 FO r a l  c a v i t y 320I V A M o d e r a t e l y
3 2 6 0 FO r a l  c a v i t y 320I V A W e l l
3 3 3 8 M P h a r y n x 410I V A P o o r l y
3 4 6 2 FL a r y n x 120I V A M o d e r a t e l y
3 5 6 8 M L a r y n x 320I V A M o d e r a t e l y
3 6 6 8 M O r a l  c a v i t y 410I V A M o d e r a t e l y
3 7 5 0 M O r a l  c a v i t y 320I V A P o o r l y
3 8 6 1 FP h a r y n x 220I V A P o o r l y
3 9 6 2 M L a r y n x 320I V A P o o r l y
4 0 5 3 M L a r y n x 420I V A W e l l
4 1 8 4 FL a r y n x 400I V A W e l l
4 2 5 0 M O r a l  c a v i t y 400I V A P o o r l y
4 3 5 5 M O r a l  c a v i t y 400I V A M o d e r a t e l y
4 4 7 3 FO r a l  c a v i t y 410I V A P o o r l y
4 5 7 1 M O r a l  c a v i t y 400I V A M o d e r a t e l y
4 6 4 9 M O r a l  c a v i t y 400I V A W e l l
4 7 5 4 M O r a l  c a v i t y 420I V A P o o r l y
4 8 7 2 M P h a r y n x 410I V A M o d e r a t e l y
4 9 5 9 M L a r y n x 420I V A M o d e r a t e l y
5 0 6 8 M L a r y n x 430I V B M o d e r a t e l y
5 1 5 4 M L a r y n x 330I V B M o d e r a t e l y
5 2 6 1 M P h a r y n x 430I V B M o d e r a t e l y
5 3 7 2 M O r a l  c a v i t y 331I V C W e l l
Site, sex, clinical stage, T and N stage and tumor differentiation are included.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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Dr. S Stevenson (Care of Prof. Alan Perkins) University of
Nottingham, UK [13] and CT33, a rabbit polyclonal anti-
body developed after immunization with a synthetic pep-
tide corresponding to the COOH-terminal 17 amino acids
of the intracytoplasmic tail of MUC1, provided by Dr. K.
Chul Kim, Lovelace Respiratory Research Institute, Albu-
querque, NM, USA [14].
Immunohistochemistry
Immunohistochemistry was performed according to
standard procedures and as previously reported [15]. Sur-
gical specimens were embedded in paraffin, 4 μm sections
were cut and placed in bovine serum albumin (BSA)
(Sigma, USA) coated slides.
Samples were dewaxed in xylol, rehydrated and endog-
enous peroxidase activity was blocked by treatment with
0.3% H2O2 (Merck, Germany) in methanol; slides were
incubated in 10% horse normal serum in phosphate buff-
ered saline (PBS) 1% BSA to eliminate background reac-
tions and antigenic recuperation was performed by
heating at 100°C in 10 mM sodium citrate buffer.
Slides were incubated overnight with the primary Ab
together with negative controls with PBS at 4°C; after
incubation with secondary peroxidase labeled Ab, reac-
tion was developed with 3-3'diaminobencidine (Sigma,
USA) and H2O2 (Merck, Germany) in PBS.
Finally, sections were counterstained with hematoxylin
(Sigma, USA), dehydrated and coverslipped with mount-
ing media. Samples were evaluated under a light micro-
scope and a positive reaction was considered when more
than 5% of the neoplasic cells were stained. Staining
intensity was scored in a semiquantitative manner [16]
and was graded as negative (-), low (+), moderate (++)
and strong (+++). Patterns of reaction were classified as
linear (plasma membrane), cytoplasmic, mixed (linear
and cytoplasmic) and nuclear following other authors
[17,18] with some modifications [15].
Three co-authors (AS-E, MVC and MR) performed a
blinded analysis of all samples included; Prof. Amada
Segal-Eiras is Professor on Pathology (Faculty of Medical
Sciences, UNLP, Argentina).
Precipitation of circulating immune complexes in 
polyethylene glycol (PEG) 3,5%
One hundred μl serum sample were mixed with 900 μl of
borate buffer (50 mM boric acid and 5 mM sodium
borate, pH 8.5) and 1000 μl of 7% PEG 6000 (Fluka AG,
Switzerland) in borate buffer, incubated overnight at 4°C
and centrifuged at 8000 rpm for 30 minutes at 4°C. Pre-
cipitates were resuspended in 2 ml of 3.5% PEG and cen-
trifuged at 7883 g for 30 minutes at 4°C. The supernatant
was discarded and the pellet was resuspended in 2 ml of
0.1 N sodium hydroxide. Absorbance was read at 280 nm.
A cut off point obtained from the negative control group
was calculated at 0.229 OD (cut off = 0.171 + 2 SD) [19].
Isolation of circulating immune complexes by protein A 
sepharose-CL4B affinity chromatography
One ml of patient serum was employed following the
same procedure described above. Circulating immune
complexes were resuspended in 1 ml PBS, applied to a 15
× 1 cm protein A sepharose CL4B column (Sigma, USA)
and incubated for 30 min at 4°C. Unbound material was
eluted with 15 ml of PBS and 1 ml fractions were col-
lected. For circulating immune complexes recovery, 5 ml
of 50 mM glycine chloride (pH 2.8) was added to the col-
umn, mixed and incubated for 30 minutes at 4°C fol-
lowed by elution with 10 ml of glycine chloride, collecting
1 ml fractions.
Protein concentration was monitored by absorbance
measurement at 280 nm and the protein peak containing
fractions were thoroughly dialyzed.
Identification of tumor antigens in circulating immune 
complexes by SDS-PAGE and Western blotting
Electrophoretic separation of proteins [20] was performed
with discontinuous 4% stacking-10% resolving polyacry-
lamide gels in reducing conditions employing a miniVE
Vertical Electrophoresis System (Amersham Biosciences
Corp., USA). Gels were electroblotted into nitrocellulose
membranes (Schleicher & Schuell GmbH, Germany),
which were blocked with TRIS buffered saline (TBS) 3%
BSA at 4°C overnight and after five washes with TBS mem-
branes were incubated with primary antibody at 4°C
overnight [21]. Nitrocellulose membranes were washed
and incubated with peroxidase conjugated goat anti-
mouse IgG or IgM (1:400) in TBS 3% BSA at room tem-
perature for 3 hours. Finally, reaction was developed with
3.3'diaminobencidine (Sigma, USA) and H2O2  (Merk,
Germany) in 10 mM TRIS buffer.
Serum MUC1 determination
Levels of serum MUC1 were measured employing a com-
mercial enzyme-linked immunosorbent assay (ELISA) fol-
lowing manufacturer instructions. The Cancer Associated
Serum Assay (CASA) (Medical Innovations Ltd, Australia)
utilizes two anti MUC1 core protein monoclonal antibod-
ies, BC2 (IgG) as catcher and BC3 (IgM) as tracer, both
directed to MUC1 peptide epitope APDTR. Reaction was
detected by a peroxidase labeled anti-mouse IgM and 2,2'-
azino-bis (3-ethylebenzythiazoline-6-sulfonic acid)
(ABTS; Sigma, USA). Optical density (OD) was read at
405 nm, MUC1 levels were extrapolated from a standard
curve and the cut off employed was 4 U/ml.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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Serum anti-MUC1 antibodies detection
Detection of antibodies reactive with the protein core of
MUC1 was performed by an ELISA described by von
Mensdorff-Pouilly [22] with some modifications [23].
Briefly, 100 μl/well of 1 μl/ml BSA were dispensed onto
3912 Falcon III flexible PVC 96 wells plates (BD Labware,
USA) and dried overnight at 37°C. After washing, 50 μl of
a 100mer peptide containing five tandem repeats of the
MUC1 core protein (100 μ/ml) and 50 μl of carbodiimide
(1-cycloexil-3-[2 morpholinoethyl] carbodiimide metho-
p-sulphonate (Sigma, USA) were dispensed in duplicates.
For each sample, 2 wells were incubated with carbodiim-
ide-peptide and two other wells were employed as con-
trols containing 100 μl of blocking buffer (1% BSA PBS)
at 4°C overnight. After washing, 150 μl of blocking buffer
was added and incubated at room temperature for 1 hour.
Plates were washed and diluted human serum samples in
blocking buffer (1:80 for IgM and 1:40 for IgG determina-
tions) were applied and incubated overnight at 4°C. After
washing, 50 μl of peroxidase conjugated goat anti-human
IgM 1:400 or IgG 1:600 (Sigma, USA) in PBS Tween-BSA
0.1% were dispensed and incubated for 1 hour at room
temperature. Finally, the reaction was developed with 50
μl of freshly prepared ABTS in 0.1 M citric acid and 0.2 M
Na2PO4H (pH 5) with H2O2. After 1 hour at room tem-
perature in the dark, OD was read at 405 nm. Free anti-
MUC1 core antibody levels were calculated as the differ-
ence between the averages of carbodiimide-peptide wells
and controls. Cut off was 0.340 OD for anti-MUC1 IgM
and 0.274 for IgG Abs.
Statistical analysis
Multivariate Principal Component Analysis was applied
to standardized variables and a correlation table was
obtained. Variables (vectors) were plotted against the two
principal components extracted (Factor 1 in x axis and
Factor 2 in y axis). ANOVA test with post hoc comparisons
of means (Tukey's test) was employed to find differences
among groups; nonparametrical correlations (Kendall's
Tau) were applied when necessary. Statistical significance
was set to p < 0.05 in all cases; calculations were per-
formed with STATISTICA for Windows, StatSoft, Inc.
(1998), Tulsa, OK, USA.
Results
MUC1 tumor expression by immunohistochemistry
Tissue MUC1 expression from 50 HNSCC tumor samples
was studied employing two different anti MUC1 antibod-
ies (Table 2). CT33 Ab, reactive with MUC1 cytoplasmic
tail, was present in 40 (80%) HNSCC specimens, 22/25
tumors localized in oral cavity, 11/16 in the larynx and 7/
9 in the pharynx. Reaction pattern was similar to previous
reports developed in breast cancer employing the CT2
monoclonal antibody directed against the same last 17 aa
of the MUC1 cytoplasmic tail (Croce et al, 2003). Cell
membrane staining with a linear pattern was observed in
34 (68%) specimens, a cytoplasmic reaction was obtained
in 32 (64%) samples while 27 (54%) had a mixed pattern
(Fig. 1b). Also, a nuclear staining was displayed in 4 (8%)
specimens. There were no statistically significant differ-
ences in MUC1 cytoplasmic tail expression related to
tumor stage, localization or differentiation, although a
clear tendency of negative CT33 reaction was found in
advanced stage tumors while nuclear staining was associ-
ated with poorly differentiated tumor areas.
C595 monoclonal antibody, directed to the protein core
of MUC1 extracellular domain, showed a positive reac-
tion in 9 samples (18%), 6/25 localized in oral cavity, 2/
17 in the larynx and 1/9 in the pharynx. Well differenti-
ated tumors showed a strong reaction limited to the cyto-
plasm and cell membrane and mainly located in areas
with keratin. In moderately and poorly differentiated
tumors, a reaction was observed along the cytoplasm with
a microvesicular pattern. No correlation was found
between C595 monoclonal antibody reactivity versus
tumor stage, node status or tumor differentiation. An
example of C595 staining is depicted in Fig. 1a.
MUC1 serum levels
Serum MUC1 levels were measured in 53 HNSCC patients
by means of ELISA. MUC1 serum levels were higher in
Table 2: Immunohistochemical results.
Antibody Positive/Total %
C595 (MUC1 Extracellular Domain) 9/50 18
Mixed 4/50 8
Linear 2/50 4
Cytoplasmic 3/50 6
CT33 (MUC1 Cytoplasmic Tail) 40/50 80
Mixed 27/50 54
Linear 34/50 68
Cytoplasmic 32/50 64
Nuclear 4/50 8
Results are expressed as positive cases over total number of cases and percentage, discriminated by immunohistochemical reaction pattern.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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a – Immunohistochemical detection of MUC1 extracellular epitopes Figure 1
a – Immunohistochemical detection of MUC1 extracellular epitopes. A stage III larynx carcinoma specimen incu-
bated with anti-MUC1 C595 monoclonal antibody is shown. Cell membrane and cytoplasm are stained over all the picture with 
a microvesicular pattern. Staining is strong inalmost all cells as well as in high proportion of intercellular connections. b – 
Immunohistochemical detection of MUC1 cytoplasmic tail epitopes. Section of a stage IV larynx carcinoma incubated 
with CT33 antibody is shown. Different cellular patterns are identified. Intense reaction is observed along the cytoplasm with a 
granular pattern and linear at nuclear membrane. Plasma membrane is partially stained. Cells are polymorphic as well as nuclei, 
showing different size and vesicular nuclear patterns. Some intercellular bridges are also stained with this antibody.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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cancer patients (mean = 2.46 U/mL, SD = 3.46 U/mL)
than controls (mean = 0.60 U/mL, SD = 0.69 U/mL); the
percentage of individuals over the cut off value (4 U/mL)
was 8/53 (15%) vs 2/18 (10.5%), respectively. Through
multivariate Principal Component Analysis, in HNSCC, a
positive correlation was found between immunohisto-
chemistry MUC1 detection and Cancer Associated Serum
Assay levels (Kendall τ = 0.275, p = 0.005; Fig. 2).
Anti-MUC1 humoral immune response analysis
Anti-MUC1 Ab detection
Free anti-MUC1 serum Ab levels measured in HNSCC
were lower than normal sex and age matched controls.
Anti-MUC1 IgM mean value in cancer patients was 0.085
OD versus 0.194 OD in controls and anti-MUC1 IgG
mean was 0.097 OD vs 0.171 OD. A negative correlation
between IgG and IgM levels (Kendall τ = -0.309, p =
0.001) was found. Both anti-MUC1 IgG and anti-MUC1
IgM were statistically correlated with MUC1 serum levels
(Fig. 3), while IgG levels were detected according to
MUC1 levels, anti-MUC1 IgM levels were very low in
those patients over MUC1 cut off levels (4 U/mL). This
association was also found by the multivariate Principal
Component Analysis; in Fig. 2 the vectors representing
anti-MUC1 IgG and IgM are drawn opposed, while the
vector that represents serum MUC1 was at the same quad-
rant of anti-MUC1 IgG.
Circulating immune complexes in HNSCC patients
Fifty three HNSCC patients presented a mean circulating
immune complexes value of 0.224 OD (SD = 0.103 OD)
statistically different from normal negative controls
(mean = 0.171 OD, SD = 0.029; p = 0.038) and positive
controls (SLE patients), mean = 0.456 OD, SD = 0.121
OD; p < 0.001. Tumor stage was statistically associated
with circulating immune complexes levels (Fig. 4); two
way ANOVA test with post hoc analysis of means showed
differences between T2 and T3 tumors versus T4 although
node invasion did not present any difference. Also, a sta-
tistical significant difference was found between well dif-
ferentiated and moderately differentiated tumor samples,
which presented a large amount of circulating immune
Multivariate Principal Component Analysis of clinical and histopathological data and tissue and serum expression of MUC1 Figure 2
Multivariate Principal Component Analysis of clinical and histopathological data and tissue and serum expres-
sion of MUC1. Each variable is represented by vectors, which longitude correspond to the weight of the variable in the 
model, and their projection to both axes corresponds to the weight of the two main factors extracted (Factor 1 and Factor 2). 
These two factors explain 39% of the variations observedin the model. This percentage is remarkable taking into account that 
variables belong to patients. CIC = Circulating immune complexes levels; T = Tumor stage; N = Node status; DIF = tumor dif-
ferentiation; CASA = Serum MUC1 levels; IgM Ab = free anti-MUC1 IgM antibodies; IgG Ab = free anti-MUC1 IgG antibodies; 
C595 = MUC1 extracellular domain expression; CT33 = MUC1 Cytoplasmic tail expression.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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complexes (p < 0.05) (Fig. 5). On the other hand,
although undifferentiated tumors had circulating
immune complexes levels similar to well differentiated
tumors, no statistical difference was found between poor
versus moderately differentiated specimens. Elevated cir-
culating immune complexes levels were found in 16/53
patients (30.2%) which belonged to tumor stage I 1/3
(33%), stage III 3/15 (20%) and stage IV 12/30 (40%).
Identification of tumor antigens isolated from circulating 
immune complexes
Eight out of 16 (50%) serum samples contained MUC1-
CIC; results are shown in Table 3. In each case, clinical
data have been included. In Fig. 6, results found in two
patients are depicted, Western blot employing C595 mon-
oclonal antibody showed a double band at about 200
kDa. Also, bands at the molecular weight ranging from 25
to 60 kD were observed which correspond to Ig light and
heavy chains. No statistical correlation was found
between MUC1-CIC and tumor or sera MUC1 expression.
Principal component analysis correlation studies
Multivariate analysis of MUC1 expression, anti-MUC1
immune response and clinical and pathological parame-
ters in HNSCC showed that histological detection with
CT33 and C595 Abs were associated with serum MUC1
levels. Moreover, serum MUC1 levels were positively cor-
related with anti-MUC1 IgG free antibodies and inversely
correlated with anti-MUC1 IgM. This suggested an associ-
ation between the presence of MUC1 in serum and the
type of antibody response.
Vectors representing circulating immune complexes were
associated with advanced tumor T stage which may indi-
cate that a large tumor mass produces the MUC1 mucin
that reacts with antibodies, forming circulating immune
complexes.
Correlation between serum MUC1 levels measured by Cancer Associated Serum Assay (U/mL) and free anti-MUC1 antibodies Figure 3
Correlation between serum MUC1 levels measured by Cancer Associated Serum Assay (U/mL) and free anti-
MUC1 antibodies. Serum MUC1 levels were plotted in abscises against anti-MUC1 IgG Abs (left coordinates) and IgM Abs 
(right coordinates). A negative correlation between serum MUC1 levels versus anti-MUC1 IgM Abs (τ = -0.266; p < 0.05) and 
a positive correlation between serum MUC1 levels and IgG Abs are observed (τ = 0.194; p < 0.05).BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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Finally, as expected, we found an association between
advanced T stage, advanced node status and poor tumor
differentiation. Interestingly, the vectors that represent
these variables were opposed to serum MUC1 and anti-
MUC1 IgG antibody levels.
Discussion
In our knowledge this is the first report that employs an
anti MUC1 cytoplasmic tail Ab in HNSCC; it revealed a
high cellular expression of MUC1 (80% of malignant
samples).
In previous studies developed in colon and breast cancer
[13,14], we have found similar results. The MUC1 cyto-
plasmic tail amino acid sequence contains seven tyrosine
residues constituting intracellular signaling motifs [22]
which play important roles in cell response to external
stimuli and is related to different oncogenes and genes
controlling the cell cycle [23,24][25,26] and β-catenin
[27]. Furthermore, it has been reported that in vivo,
MUC1 cytoplasmic tail regulates erbB receptors signaling
through the activation of MAPK pathways [28].
These observations clearly demonstrate the transforming
properties of MUC1 overexpression in carcinoma and
emphasize the importance of MUC1 cytoplasmic tail sub-
cellular localization. In HNSCC we have found extensive
expression and cellular localization of MUC1 cytoplasmic
tail; large and poorly differentiated tumors were likely to
be less reactive with CT33 and C595 Abs.
When C595 (anti-extracellular MUC1) monoclonal anti-
body was assayed, a lower percentage of reactivity with
respect to anti-MUC1 cytoplasmic tail was found; we have
previously reported a high reactivity to MUC1 protein
core epitopes in HNSCC [7,8]. The difference among
results was expected since previous reports included a
larger number of tumors localized in oral cavity (58%) in
comparison with 49.1% in the present report; we found
that this localization is reactive with anti-protein core
monoclonal antibodies [7]. On the other hand, results
presented here corresponded to 18.9% of pharyngeal
tumors which did not usually react with these mono-
clonal antibodies; in past reports, only one patient with a
pharyngeal tumor was included [7]. MUC1 cytoplasmic
Comparative analysis of circulating immune complexes' levels (OD 280 nm) among different primary tumor T stages Figure 4
Comparative analysis of circulating immune complexes' levels (OD 280 nm) among different primary tumor T 
stages. Circulating immune complexes' levels in HNSCC increased with tumor T stage (F = 5.375; p < 0.05).BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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tail reactivity is not affected by MUC1 glycosylation and
sialylation and, consequently, represents a better indica-
tor of cell membrane associated MUC1 [15]. Other
authors [29-31] have described MUC1 RNA splice variants
which do not express the protein core region. Our results
also showed that serum MUC1 levels were elevated in
15% of HNSCC samples; interestingly, we found a statis-
tically significant correlation between serum and tumor
MUC1 detection indicating that this mucin may possibly
be released by the tumor.
In this research we found anti-MUC1 antibodies; also, we
observed that serum MUC1 levels were positively corre-
lated with free anti-MUC1 IgG, which may indicate that
an anti-MUC1 immune response is mounted. Tumor
derived MUC1 is known to induce cellular and humoral
specific immune responses in cancer patients [32-34]. In
this context, it is possible to speculate that a specific anti-
MUC1 immune response is induced in HNSCC patients.
In another report [11], we pointed out that low MUC1
serum levels in stage I breast cancer patients were associ-
ated with the presence of free and complexed anti-MUC1
antibodies. Similarly, circulating anti-MUC1-IgG anti-
body levels were found predictive of survival in breast [35]
and pancreatic cancer patients [34]. We have found that
anti-MUC1 IgG Ab correlated negatively with poor
HNSCC differentiation and disease stage which are the
main predictors for patient outcome in this localization.
Furthermore, we proved that MUC1-CIC detected by
Western blot were of the IgG isotype since isolation was
performed by protein A Sepharose CL-4B chromatogra-
phy, which is known to bind with high affinity to 1, 2 and
4 IgG classes.
Presence of high amounts of circulating immune com-
plexes in cancer patients is not very well understood. Anti-
body formation may represent the onset of an anti tumor
immune response but, on the other hand, may be the con-
sequence of tumor immune evasion related to a defective
cellular immune response. Nonetheless, circulating
immune complexes have been associated with tumor pro-
gression and also, their formation clearly affects the cor-
rect evaluation of several tumor markers.
Only a few reports in the literature have described the
antigenic component of circulating immune complexes in
HNSCC. Vlock DR and others [36] have exhaustively stud-
ied the reactivity of serum Abs against autologous tumor
cell lines. These authors found that some patients pre-
sented high Ab titers which occasionally cross reacted
with tumor cell lines derived from other histogenesis.
In accordance with other reports [37,38], we found higher
circulating immune complexes levels in HNSCC patients
in comparison with normal subjects; furthermore, we also
agree with these authors that elevated circulating immune
complexes levels were detected in advanced tumor stage.
They pointed out that high circulating immune complexes
levels in HNSCC patients is the result of increased tumor
Western Blot analysis of circulating immune complexes' fractions eluted and isolated from affinity chromatography Figure 5
Western Blot analysis of circulating immune complexes' fractions eluted and isolated from affinity chromatog-
raphy. Circulating immune complexes were obtained from a patient with a stage IV larynx tumor. Lane 1: 3.5% PEG precipi-
tate; lane 2: PBS eluate from protein A Sepharose CL-4B column and lane 3: glycine HCl eluate. In lanes 1 and 3 a double band 
at about 200 kD is observed.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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mass which would mediate changes in anti tumor immu-
nity. Moreover, Das TK et al [39] found that circulating
immune complexes persist after surgical excision of the
primary tumor due to the presence of remaining tumor
tissue or occult metastasis.
MUC1 is a mucin that has been detected both in the cyto-
plasm, plasma membrane and nucleus in different tumor
localizations. MUC1 is synthesized in the ER and glyco-
sylated in the Golgi apparatus but it has been described
that it suffers several glycosylation cycles being expressed
in the plasma membrane several times [40]. Furthermore,
different splicing variants have been described that can be
present in the cytoplasm and in the plasma membrane, as
well [31,41-43]. Wen et al [44] investigated intracellular
trafficking of MUC1 cytoplasmic tail in human pancreatic
cancer cell lines S2-013 and Panc-1 and detected this frac-
tion at the inner cell surface, in the cytosol and in the
nucleus. They hypothesized that the association between
β-catenin and fragments of the MUC1 cytoplasmic tail
facilitated the cytosol-to-nuclear translocation of β-cat-
enin and contributed to its nuclear accumulation. We
have found [14] MUC1 cytoplasmic tail and protein core
expression in the plasma membrane, cytoplasm and
nucleus in breast and colorectal tumor samples.
Conclusion
In HNSCC, Principal Component Analysis (Fig. 2)
showed that circulating immune complexes were associ-
ated with advanced tumor stage; furthermore, the vectors
that represent these variables did not positively correlate
to serum MUC1 and anti-MUC1 IgG antibody levels, and
also were inversely correlated with MUC1 tumor expres-
sion. Considering that we identified MUC1 as an anti-
genic component of circulating immune complexes, taken
together, these results indicate that a large tumor mass
produces high MUC1 mucin that is liberated to circula-
tion and captured by IgG antibodies forming MUC1-CIC.
Another interesting conclusion is that poorly differenti-
ated tumors are inversely correlated with tumor and
serum MUC1 detection. This finding suggests the possibil-
ity to take into account its consideration regarding prog-
nosis and follow up of this disease.
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Table 3: Data from HNSCC patients' serum employed to isolate circulating immune complexes.
Sample Localization Stage Sex Age Differentiation MUC1 In 
CIC
MUC1 in 
IHQ
MUC1-CT in 
IHQ
CIC levels 
(OD)
MUC1 serum levels (U/mL)
1 Larynx I M 52 Poorly + - - 0.306 3.9
2 Larynx III M 64 Well + - - 0.371 1.4
3 Larynx III M 56 Moderately + - + 0.320 1.2
4 Larynx III M 70 Moderately + - + 0.229 0.9
5 Larynx IVA M 58 Poorly - - + 0.411 2.2
6 Larynx IVA M 53 Moderately - - + 0.312 1.7
7 Oral Cavity IVA M 55 Moderately - + + 0.322 4.7
8 Oral Cavity IVA F 29 Moderately + - + 0.258 1.7
9 Oral Cavity IVA M 68 Moderately + - + 0.323 1.1
10 Oral Cavity IVA M 55 Moderately - - - 0.477 0.6
11 Oral Cavity IVA M 49 Well - - + 0.403 0.7
12 Pharynx IVA M 56 Moderately - - - 0.497 5.3
13 Pharynx IVA M 65 Moderately + - + 0.335 1.9
14 Pharynx IVA M 38 Poorly + + + 0.231 1.8
15 Pharynx IVA M 72 Moderately - - - 0.473 0.4
16 Pharynx IVB M 61 Moderately - - + 0.349 1.5
Positive/Total or 
mean value
8/16 2/16 11/16 0.351 2.0
Clinical data with immunohistochemical detection and serum determination of MUC1, anti-MUC1 Abs and circulating immune complexes are 
depicted.BMC Cancer 2006, 6:253 http://www.biomedcentral.com/1471-2407/6/253
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